Trifluridine/tipiracil in the treatment of gastric cancer

Trifluridine/tipiracil is a compound drug, approved in 2015 by the Food and Drug Administration, and in 2016 by the European Medicines Agency, for the treatment of chemorefractory metastatic colorectal cancers, after the phase 3 RECOURSE trial demonstrated significant benefit. Another phase 3 trial (TAGS) showed significant improvement of overall survival and progression-free survival in refractory gastric cancer and gastroesophageal junction cancer, leading to further approval from the FDA on February 2019, followed by Japan in August 2019 and the European Union in September 2019. As promising results have already been observed in the chemorefractory gastric and gastroesophageal-junction cancers, ongoing trials are assessing the use of trifluridine/tipiracil with other standard of care agents, aiming to further improve the survival rate of these patients.

Automated summary

Trifluridine/tipiracil is a compound drug approved for the treatment of chemorefractory colorectal, gastric, and gastroesophageal junction cancers. Promising results have been observed, leading to further studies investigating its use in combination with other standard of care agents to improve patient survival rates.